Olutasidenib (IDH1 inhibitor, post-transplant maintenance)

Current understanding

To be populated as evidence accumulates.

Evidence log

• 2026-06-23 — A Pragmatic Clinical Trial to Prevent Relapse for Myeloid Malignancies With Measurable Disease Prior to Allogeneic Transplant: cross-connection with post-transplant-maintenance-hma: Both pages address post-transplant maintenance for myeloid malignancies; the MRD-guided pragmatic trial framework could subsume mutation-directed maintenance arms like olutasidenib for IDH1-mutant disease. (novelty: 3)
• 2026-05-20 — A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm: cross-connection with olutasidenib-hma-combination: Both pages cover olutasidenib (IDH1 inhibitor) in MPN-adjacent contexts — combination with HMA in active disease vs. post-transplant maintenance monotherapy. (novelty: 3)
• 2026-03-30 — Inqovi Maintenance Therapy in Myeloid Neoplasms: cross-connection with astx727-cedazuridine-decitabine: Both agents are being prospectively evaluated as post-transplant maintenance in myeloid neoplasms, representing parallel strategies (HMA vs. IDH1 inhibitor) to reduce relapse after allo-SCT. (novelty: 3)
• 2026-03-05 — Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant: Phase I trial (early trial data) launched to evaluate safety, tolerability, and efficacy of olutasidenib as post-alloHCT maintenance to prevent relapse in IDH1-mutated AML, MDS, or CMML — first prospective study extending IDH1 inhibition into the post-transplant maintenance setting. (novelty: 3)

Open questions

Related